Rejected at 7:09 a.m. Jun, 13, 2024 ] by Cameron
Author: celembar
Related Note: 1495823891256 1
Rationale for change

Can we change the verb "reduce" to "prevent" or something similar - reduce doesn't make as much sense here - a bit confusing

Rejection reason

Means the same thing; reduce the number of crises

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step2_v12::#B&B::07_Hematology_and_Oncology::01_Red_Cells::07_Sickle_Cell_Disease::Extra #AK_Step1_v12::#AMBOSS::sQatx4 #AK_Step1_v12::#OME::04_Organ_Systems::05_Hematology_Oncology::02_Anemia::07_Normocytic_Anemia #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::24_Hydroxyurea #AK_Step1_v12::#Pixorize::^Missing_image #AK_Step1_v12::#OME::Clinical::04_Organ_Systems::05_Hematology_Oncology::02_Anemia::07_Normocytic_Anemia #AK_Step2_v12::#Bootcamp::Pediatrics::04_Hematology_and_Oncology::01_Anemias::01_Sickle_Cell_Disease #PANCE::HEME::hereditary_disorders #AK_Step2_v12::#AMBOSS::Lf0w52 #AK_Step1_v12::#B&B::04_Biochem::01_Molecular::03_Pyrimidine_Metabolism::Extra #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::08_Cancer_therapy-cell_cycle::*Hydroxyurea #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::12_Antimetabolites::*Pyrimidine_Synthesis_Inhibitors::Hydroxyurea #AK_Step2_v12::#UWorld::COMLEX::100581 #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::04_Normocytic_Anemia::03_Sickle_Cell_Anemia #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::01_Antimetabolites::01_Methotrexate,_leucovorin,_5-fluorouracil,_hydroxyurea::zanki_extra #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::22_Normocytic_Anemia_(Clinical_Medicine) #AK_Step1_v12::#Bootcamp::Pulmonology::03_Blood_Physiology::05_Hemoglobin #AK_Step1_v12::#AMBOSS::MiaMH4 #AK_Step2_v12::#UWorld::Step::3786 #AK_Other::Only_Step_1&2_Overlap #AK_Step2_v12::#UWorld::Step::19715 #AK_Step1_v12::#Bootcamp::Genetics::07_High_yield_genetic_disorders::02_Key_Mutations:_Cystic_Fibrosis_&_Sickle_Cell_Anemia #AK_Step1_v12::#B&B::12_Hematology::04_Cancer_Drugs::01_Antimetabolites::Extra #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#Bootcamp::Genetics::01_DNA_Structure::05_Clinical_Applications_of_the_Pyrimidine_Pathway #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::01_Antimetabolites::01_Methotrexate,_Leucovorin,_5-fluorouracil,_Hydroxyurea #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::10_Cell_Cycle_Dependent_Drug_Targets #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::10_Cell_Cycle_Dependent_Drug_Targets #AK_Other::^EXPN